SPA
AKYA

Sherbrooke Park Advisers’s Akoya BioSciences AKYA Stock Holding History

Sherbrooke Park Advisers’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,960
Closed -$74.9K – 877
2024
Q1 		$74.9K Buy
+15,960
New +$82.9K 0.01% 809

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Sherbrooke Park Advisers's AKYA Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Akoya BioSciences (AKYA) in Q2 2024, closing a stake of 15,960 shares — an estimated $74.9K sold.

Sherbrooke Park Advisers first reported a position in AKYA in Q1 2024 and held it in 1 quarter. The position peaked at $74.9K in Q1 2024. 59 funds tracked by Wall St. Rank hold AKYA as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Akoya BioSciences position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 15,960 Akoya BioSciences shares in Q2 2024, an estimated $74.9K.
  • Sherbrooke Park Advisers first reported a position in Akoya BioSciences in Q1 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Akoya BioSciences position peaked at $74.9K in Q1 2024.
  • 59 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.